Published in Oncotarget on March 21, 2017
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature (2010) 9.95
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem (1998) 6.84
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell (2008) 6.62
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40
Mechanisms of Taxol resistance related to microtubules. Oncogene (2003) 3.16
Apoptosis and cancer: mutations within caspase genes. J Med Genet (2009) 2.80
Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res (2008) 2.56
Molecular requirements for kinetochore-associated microtubule formation in mammalian cells. Curr Biol (2006) 2.48
How do anti-mitotic drugs kill cancer cells? J Cell Sci (2009) 2.38
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther (2009) 2.10
Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents (2005) 2.10
How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets (2007) 2.05
Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res (2011) 1.99
Killing cells by targeting mitosis. Cell Death Differ (2012) 1.65
Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res (2001) 1.60
Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis (2012) 1.60
Apoptosis in the absence of caspase 3. Oncogene (2001) 1.57
Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol Biol Cell (2011) 1.53
Mitosis and apoptosis: how is the balance set? Curr Opin Cell Biol (2013) 1.53
An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res (2012) 1.49
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev (2012) 1.42
Unwinding the loop of Bcl-2 phosphorylation. Leukemia (2001) 1.36
Control of microtubule organization and dynamics: two ends in the limelight. Nat Rev Mol Cell Biol (2015) 1.31
Stochastic competition between mechanistically independent slippage and death pathways determines cell fate during mitotic arrest. PLoS One (2010) 1.28
Microtubules: a dynamic target in cancer therapy. IUBMB Life (2008) 1.24
Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther (2010) 1.23
Localized RanGTP accumulation promotes microtubule nucleation at kinetochores in somatic mammalian cells. Mol Biol Cell (2008) 1.16
Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm Des (2010) 1.13
Targeting Mitosis in Cancer: Emerging Strategies. Mol Cell (2015) 1.11
Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther (2014) 1.08
Somatic mutations of CASP3 gene in human cancers. Hum Genet (2004) 1.05
Antimitotic drugs in cancer chemotherapy: promises and pitfalls. Biochem Pharmacol (2013) 1.04
Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J Med Chem (2012) 1.03
How Taxol/paclitaxel kills cancer cells. Mol Biol Cell (2014) 1.03
The tubulin colchicine domain: a molecular modeling perspective. ChemMedChem (2011) 1.00
Survival of aneuploid, micronucleated and/or polyploid cells: crosstalk between ploidy control and apoptosis. Mutat Res (2007) 0.97
The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest. Nat Commun (2015) 0.97
New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta (2011) 0.96
Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. Cancer Res (2009) 0.93
RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner. Oncogene (2009) 0.92
Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. Open Biol (2015) 0.92
βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget (2015) 0.90
Importin-β negatively regulates multiple aspects of mitosis including RANGAP1 recruitment to kinetochores. J Cell Biol (2012) 0.89
Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability. J Med Chem (2011) 0.89
MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell (2015) 0.88
Mitosis as an anti-cancer drug target. Chromosoma (2013) 0.88
Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle (2005) 0.87
Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization. Eur J Med Chem (2011) 0.83
The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis (2008) 0.82
Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget (2015) 0.82
Differential responses of mitotic spindle pole formation to microtubule-stabilizing agents epothilones A and B at low concentrations. Cell Cycle (2007) 0.81
Mcl-1 dynamics influence mitotic slippage and death in mitosis. Oncotarget (2016) 0.80
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Oncotarget (2016) 0.80
The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy. Oncotarget (2014) 0.80
New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. J Med Chem (2015) 0.79
Genes that modulate the sensitivity for anti-microtubule drug-mediated chemotherapy. Curr Cancer Drug Targets (2010) 0.79
Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells. Mol Biol Cell (2011) 0.78
Visualization of aberrant perinuclear microtubule aster organization by microtubule-destabilizing agents. Biosci Biotechnol Biochem (2009) 0.77
Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site. Anticancer Agents Med Chem (2016) 0.76
Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells. Cancer Biol Ther (2015) 0.76
Effects of the semisynthetic bis-indole derivative KAR-2 on store-operated calcium entry in human neutrophils. Arch Biochem Biophys (2013) 0.76